TABLE 1.
Basic demographics and medication in studied AF patients on long‐term rivaroxaban/apixaban therapy
| Parameter | Rivaroxaban‐treated patients with statin | Rivaroxaban‐treated patients without statin | Significance (p value) | Apixaban‐treated patients with statin | Apixaban‐treated patients without statin | Significance (p value) |
|---|---|---|---|---|---|---|
| Number of patients (men/women) (absolute number) | 28 (9/19) | 24 (8/16) | N/A | 28 (12/16) | 35 (10/25) | N/A |
| Age (years) | 75 (68–81) | 72 (65–83) | 0.34 | 75 (69–80) | 76 (68–84) | .64 |
| Beta‐blockers (%) | 96.4 | 91.6 | 0.88 | 96.4 | 85.7 | .12 |
| Diuretics (%) | 78.5 | 75.0 | 0.21 | 64.2 | 42.8 | .51 |
| Amiodarone (%) | 3.5 | 12.5 | 0.26 | 10.7 | 14.2 | .64 |
| Verapamil (%) | 3.5 | 8.3 | 0.65 | 0 | 5.7 | .16 |
| Digoxin (%) | 25.0 | 37.5 | 0.34 | 39.2 | 37.1 | .93 |
| ACE inhibitors, AT1RB (%) | 58.5/20.0 | 33.3/33.3 | 0.76 | 60.7/14.2 | 42.8/11.4 | .10 |
| PPI (%) | 71.4 | 45.8 | 0.23 | 60.7 | 62.8 | .87 |
| Duration of rivaroxaban/apixaban (days) | 117.5 | 117.5 | 0.75 | 110 | 110 | .96 |
| Duration of statin (days) | 90.5 | 0 | N/A | 85.5 | 0 | N/A |
| BMI (kg/m2) | 26.5 | 27.5 | 0.57 | 27.1 | 27.4 | .77 |
|
CHA2DS2VASc (score) |
4.5 | 3.9 | 0.15 | 5.3 | 5.1 | .42 |
|
HAS‐BLED (score) |
3.5 | 3.25 | 0.72 | 3.8 | 3.5 | .30 |
| Serum creatinine (umol/L) | 99.9 ± 22.9 | 111.6 ± 28.8 | 0.13 | 111.1 ± 46.7 | 116.8 ± 44.3 | .60 |
| Calculated GFR ‐ MDRD (ml/min/1.73 m2) | 60.2 | 53.7 | 0.17 | 59.0 | 51.9 | .21 |
| Total bilirubin (mmol/L) | 12.8 ± 6.6 | 19.1 ± 14.1 | 0.08 | 14.8 ± 8.8 | 13.8 ± 7.1 | .64 |
| Total serum protein (g/L) | 64.7 ± 7.5 | 62.7 ± 7.9 | 0.40 | 65.6 ± 9.8 | 63.5 ± 11.1 | .52 |
| Total serum cholesterol (mmol/L) | 4.0 ± 1.7 | 4.6 ± 1.5 | 0.31 | 4.2 ± 1.1 | 4.3 ± 1.1 | .84 |
| LDL‐cholesterol (mmol/L) | 2.1 ± 1.5 | 2.8 ± 1.4 | 0.21 | 2.4 ± 0.8 | 2.5 ± 0.9 | .72 |
| HDL‐cholesterol (mmol/L) | 1.2 ± 0.5 | 1.1 ± 0.5 | 0.94 | 1.2 ± 0.3 | 1.2 ± 0.4 | .97 |
| Triglycerides (mmol/L) | 1.4 ± 0.6 | 1.2 ± 0.5 | 0.24 | 1.3 ± 0.6 | 1.5 ± 0.9 | .45 |
| Diabetes mellitus (%) | 42.8 | 33.3 | 0.49 | 39.2 | 34.2 | .58 |
| History of stroke (%) | 42.5 | 21.7 | 0.18 | 35.7 | 28.5 | .44 |
Abbreviations: ACE, angiotensin‐converting enzyme; AT1R, AT1 receptor; BMI, body mass index; CHA2DS2VASc, Congestive heart failure or left ventricular dysfunction Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)‐Vascular disease, Age 65–74, Sex category; GFR, glomerular filtration rate; HAS‐BLED, Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage; HDL, high‐density lipoproteins; LDL, ow‐density lipoproteins; MDRD, Modification of Diet in Renal Disease; N/A, non‐applicable; PPI, proton pump inhibition.